Effectiveness of Blonanserin (cas 132810-10-7) for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis
-
Add time:08/27/2019 Source:sciencedirect.com
ObjectiveDopamine supersensitivity psychosis (DSP) is one of the key factors contributing to the development of antipsychotic treatment-resistant schizophrenia (TRS). We investigated the efficacy of Blonanserin (cas 132810-10-7), an atypical antipsychotic, for patients with TRS and DSP.
We also recommend Trading Suppliers and Manufacturers of Blonanserin (cas 132810-10-7). Pls Click Website Link as below: cas 132810-10-7 suppliers
Prev:Behavioural pharmacologyLack of dopamine supersensitivity in rats after chronic administration of Blonanserin (cas 132810-10-7): Comparison with haloperidol
Next:Dopamine D3 receptor antagonism contributes to Blonanserin (cas 132810-10-7)-induced cortical dopamine and acetylcholine efflux and cognitive improvement) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Full paperBlonanserin (cas 132810-10-7) extensively occupies rat dopamine D3 receptors at antipsychotic dose range09/03/2019
- Short CommunicationEffect of isopropyl myristate on the viscoelasticity and drug release of a drug-in-adhesive transdermal patch containing Blonanserin (cas 132810-10-7)09/02/2019
- Research reportThe atypical antipsychotic Blonanserin (cas 132810-10-7) reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets09/01/2019
- Comparative study of the efficacy and safety between Blonanserin (cas 132810-10-7) and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial08/31/2019
- Comprehensive DNA methylation analysis of human neuroblastoma cells treated with Blonanserin (cas 132810-10-7)08/30/2019
- Atypical antipsychotic properties of AD-6048, a primary metabolite of Blonanserin (cas 132810-10-7)08/29/2019
- Dopamine D3 receptor antagonism contributes to Blonanserin (cas 132810-10-7)-induced cortical dopamine and acetylcholine efflux and cognitive improvement08/28/2019
- Behavioural pharmacologyLack of dopamine supersensitivity in rats after chronic administration of Blonanserin (cas 132810-10-7): Comparison with haloperidol08/26/2019
- Blonanserin (cas 132810-10-7) ameliorates social deficit through dopamine-D3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia08/25/2019
